Your browser is old and is not supported. Upgrade for better security.

Invest in Dynaris

We set new standard in oxygen therapy; 7 patents, FDA, superior therapy, & more

Highlights

1
FDA 510 (K), EUA, ISO-13485 Quality System, FDA registered manufacturing in-house, Ready to go!
2
5.9 million patients on oxygen in the U.S. alone growing to over 7 million patients in 2023.
3
Protected by 7 U.S. Patents, more pending, foreign patents pending.
4
Experienced team with a history of success, from concept through acquisition. CEO has 28 patents
5
Superior oxygen therapy for patients. Sets a new therapeutic standard for oxygen patients.
6
Oxygen therapies are expanding to other areas; i.e. cluster headaches and wound healing treatments
7
Additional products in development expand our technologies into other therapeutic market segments.

Our Team

The founders have been face-to-face with patients in the respiratory business for more than the last 4 decades. We've seen their pain and suffering. We have seized the opportunity to greatly help them and set a new standard in oxygen therapy. Quite simply, patients ask us to help them. They're family!

Pitch

This slide contains forward-looking projections that cannot be guaranteed.


Downloads

Overview